©The Author(s) 2026.
World J Gastroenterol. Feb 7, 2026; 32(5): 113505
Published online Feb 7, 2026. doi: 10.3748/wjg.v32.i5.113505
Published online Feb 7, 2026. doi: 10.3748/wjg.v32.i5.113505
Table 2 Initial infliximab clearance, probability of mucosal healing, probability of C-reactive protein normalization, and probability of antidrug antibody for patients who received Bayesian model-guided treatment
| Patients | CL (L/day) | Probability of MHEAL | Probability of CRP normalization | Probability of ADA |
| 1 | 0.6236 | 7.42 | 19.19 | 94.47 |
| 3 | 1.1102 | 0.73 | 3.95 | 100.00 |
| 4 | 0.3160 | 39.44 | 47.78 | 56.62 |
| 5 | 0.0168 | 73.32 | 70.22 | 18.14 |
| 6 | 0.2722 | 46.50 | 52.49 | 47.96 |
| 7 | 0.3937 | 28.18 | 39.42 | 71.38 |
| 8 | 0.6329 | 7.07 | 18.56 | 94.78 |
| 9 | 0.6095 | 7.94 | 20.15 | 93.99 |
| 11 | 0.4288 | 23.95 | 35.99 | 76.34 |
| 12 | 0.5125 | 14.82 | 28.13 | 86.66 |
- Citation: Mould DR, Kutschera M, Primas C, Reinisch S, Novacek G, Lichtenberger C, Dervieux T, Bae Y, Lee SH, Lee JH, Reinisch W. Identification of strong correlations of clearance with clinical outcomes for inflammatory bowel disease. World J Gastroenterol 2026; 32(5): 113505
- URL: https://www.wjgnet.com/1007-9327/full/v32/i5/113505.htm
- DOI: https://dx.doi.org/10.3748/wjg.v32.i5.113505